Interstitial lung disease of systemic sclerosis

Area of Science:

• Pulmonary Medicine
• Rheumatology
• Cell Biology

Background:

• Pulmonary fibrosis is a severe complication of scleroderma (systemic sclerosis, SSc), leading to high morbidity and mortality.
• An inflammatory process in the alveoli and distal airways contributes to irreversible fibrosis in many SSc patients.
• Altered lung fibroblasts (myofibroblasts) may result from cytokine influence on resident fibroblasts.

Purpose of the Study:

• To investigate the inflammatory and fibrotic processes in the lungs of patients with systemic sclerosis.
• To identify key cytokines and molecular mediators involved in the pathogenesis of SSc-associated lung disease.
• To explore potential therapeutic targets by understanding the biological regulation of extracellular matrix synthesis.

Main Methods:

• Analysis of bronchoalveolar lavage (BAL) fluid from SSc patients.
• Quantification of acute-phase and chronic-phase inflammatory and fibrogenic cytokines.
• Assessment of fibroblast phenotype and activity.

Main Results:

• Increased levels of acute-phase cytokines (IL-1 alpha, TNF-alpha, MIP-1 alpha, IL-8, RANTES) and thrombin were observed in SSc BAL fluid.
• Elevated levels of chronic-phase fibrogenic cytokines (PDGF, TGF-beta) were also detected in SSc BAL fluid.
• Evidence suggests the presence of activated myofibroblasts in the fibrotic lung tissue.

Conclusions:

• Inflammation and cytokine dysregulation play a significant role in the development of pulmonary fibrosis in SSc.
• Further research into the molecular mechanisms of fibrosis is essential for effective SSc lung disease treatment.
• Targeting specific cytokines or fibroblast activation pathways may offer future therapeutic strategies.